title: Personalized immunotherapy ( AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma.
abstract: BACKGROUND
  AGS-003 is a novel autologous dendritic cell vaccine currently in Phase III clinical development in combination with sunitinib for patients with intermediate- and poor-risk clear cell metastatic renal cell carcinoma (ccmRCC).
  
  
  METHODS
  In addition to research published within the past 15 years demonstrating the efficacy of novel targeted therapies, early-phase clinical trial results recently published for AGS-003 in combination with sunitinib are discussed, as well as the ongoing Phase III clinical trial Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma.
  
  
  CONCLUSIONS
  AGS-003 in combination with sunitinib is a rational step forward for the clinical management of patients with ccmRCC. If the Phase III Advanced Renal Cell Carcinoma trial is positive, this treatment modality will provide a significant survival benefit with minimal toxicity and could change the standard of care for ccmRCC.
authors.affiliation: Cedars-Sinai Medical Center , 8700 Beverly Blvd, Los Angeles, CA , USA Robert.Figlin@cshs.org.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Figlin
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007211:Indoles / Q000008:administration & dosage*; D057285:Precision Medicine / Q000379:methods / Q000639:trends*; D011758:Pyrroles / Q000008:administration & dosage*; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib
keywords: AGS-003; VEGF; autologous dendritic cell vaccine; immunotherapy; mTOR; overall survival; renal cell carcinoma; sunitinib; targeted therapy